First-Line Treatment Study for Leukemia: Evaluating the combination of Pevonedistat
and Azacitidine Vs. Azacitidine alone
Does the combination of pevonedistat and azacitidine improve event-free survival (EFS)
when compared with single-agent azacitidine (An event is defined as death or transformation
to AML in participants with MDS or CMML, whichever occurs first, and is defined as
death in participants with low-blast AML)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The purpose of this study is to determine whether the combination of pevonedistat
and azacitidine improves event-free survival (EFS) when compared with azacitidine
alone. This study is for patients with Higher-Risk Myelodysplastic Syndromes, Chronic
Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia.
Study Reference #: ILEU17136
Lead Researcher (Principal Investigator)
Lead Researcher: Jane Liesveld, MD
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search